Paul L. Berns was named Chief Executive Officer of Neumora Therapeutics, Inc., effective August 14, 2026. As of November 6, 2026, Neumora Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on August 14, 2026, naming 1 appointment (Form 8-K, August 14, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Neumora Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Neumora Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-08-14. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Neumora Therapeutics, Inc. files it.
Layoffs on record: 1 filing or notice, latest 2026-06-15 (layoff filings and notices).
Also on the record for Neumora Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 15, 2026 | Stake report, Schedule 13G/A, by K2 HealthVentures Equity Trust LLC | 3.1% of the class | 5%+ stakes | Source |
| May 4, 2026 | Stake report, Schedule 13G/A, by Raymond Debbane | 4.7% of the class | 5%+ stakes | Source |
| April 1, 2026 | Stake report, Schedule 13D/A, by ARCH Venture Fund XII, L.P. | 18.7% of the class | 5%+ stakes | Source |
| February 19, 2026 | Stake report, Schedule 13G, by Raymond Debbane | 5.4% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by K2 HealthVentures Equity Trust LLC | 5.01% of the class | 5%+ stakes | Source |
| October 29, 2025 | Stake report, Schedule 13D/A, by ARCH Venture Fund XII, L.P. | 20.7% of the class | 5%+ stakes | Source |
| August 11, 2025 | Stake report, Schedule 13G, by K2 HealthVentures Equity Trust LLC | 6.6% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Neumora Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Neumora Therapeutics, Inc. and the records around it.
Neumora Therapeutics, Inc. elsewhere on the record
- Layoff notices Jun 2026
- 5%+ stake filings May 2026
- Who owns it
Companies that share a holder
- K2 HealthVentures Equity Trust LLC also filed stake reports on 1 other company: Alto Neuroscience, Inc. (Feb 2026)
- ARCH Venture Fund VII, L.P. also filed stake reports on 5 other companies: City Therapeutics, Inc. (Oct 2026), Parabilis Medicines, Inc. (Aug 2026), Seaport Therapeutics, Inc. (May 2026)
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
Watch Neumora Therapeutics, Inc.
Get an email when Neumora Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Neumora Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Neumora Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Neumora Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-14 | In | Chief Executive Officer | 2026-08-14 | 8-K, 2026-08-14 |
Who leads Neumora Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Paul L. Berns, appointed, effective 2026-08-14 (filed 2026-08-14).
New leaders reset buying decisions — get the Full Report on Neumora Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Neumora Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Neumora Therapeutics, Inc.Every change, in the filing's words
Appointed: Paul L. Berns, Chief Executive Officer, effective 2026-08-14
On August 14, 2026, the Company announced that Paul L. Berns, the Company's current Chief Executive Officer, will become the Company's Executive Chairperson of the Board of Directors (the "Board"), and Joshua Pinto, Ph.D., the Company's current President, will succeed Mr. Berns as the Company's Chief Executive Officer (the "Leadership Transition") effective August 14, 2026 (the "Transition Date").
- The Leadership Transition was approved by the Board on August 12, 2026.
- Dr. Pinto will also continue to serve as the Company's President.
- In connection with the Leadership Transition, on August 12, 2026, the Board also approved the appointment of Dr. Pinto as a Class III director, effective as of the Transition Date, to serve for a term expiring at the 2029 Annual Meeting of Stockholders and until his successor is elected and qualified or until his earlier death, resignation or removal.
Tools for this story
Each opens in a new tab, filled in for Neumora Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.